CancerNetwork®’s Week in Review: March 22, 2021


Take a look back at some of the important news and notes from last week in the world of oncology, featuring news about breast cancer, prostate cancer, molecular profiling, ovarian cancer, and more.

Each Monday, CancerNetwork® highlights the most important content from the previous week in oncology.

Among the most popular content from last week was a review article published in the March issue of the Journal ONCOLOGY®. The research examines the integration of approved PARP inhibitors into clinical practice to treat patients with advanced prostate cancer.

Tamoxifen or Aromatase Inhibitors Plus GnRHa Sustained Decreases in Estradiol Levels for Male Patients With Breast Cancer

Data on male patients with hormone receptor–positive breast cancer found treatment options that included gonadotropin-releasing hormone analogue (GnRHa) sustained a decrease in estradiol levels, reducing quality of life for this patient subset.

The 3-month follow-up showed that the decrease in hormonal parameters due to the addition of GnRHa to treatment was associated with decreased sexual function and quality-of-life (QOL) for patients.

Molecular Profiling and the Promise of Precision Medicine

ONCOLOGY® sat down with John L. Marshall, MD, chief of the Division of Hematology/Oncology at Medstar Georgetown University Hospital and director of the Ruesch Center for the Cure of Gastrointestinal Cancer as well as co-chair of the 6th Annual School of Gastrointestinal Oncology® (SOGO®), hosted by Physicians’ Education Resource, LLC (PER®), to discuss how personalized approaches to treating various gastrointestinal malignancies has changed the therapy landscape.

Marshall discussed the importance of profiling every patient and the improved outcomes made possible by the use of immunotherapy.

Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics

Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.

The team of investigators provided an updated review of clinical data supporting the 4 PARP inhibitors that have undergone the most investigation thus far in metastatic castrate-resistant prostate cancer.

Continuing Bevacizumab Beyond Progression Improved PFS Compared With Chemo Alone for Recurrent Ovarian Cancer

A bevacizumab-plus-chemotherapy combination improved progression-free survival for a cohort of patients with recurrent platinum-sensitive ovarian cancer, suggesting the potential for a future therapeutic path in clinical practice.

The study sought to determine the value of continued bevacizumab treatment after progression following first-line treatment.

Individualized PET4-Guided Treatment Allows Omission of Radiotherapy for Patients With Hodgkin Lymphoma

Combination chemotherapy treatment followed by individualized PET4-guided therapy allowed some patients with unfavorable Hodgkin lymphoma to forego radiotherapy while maintaining efficacy.

“This new treatment strategy could be applicable to clinical practice, where the medical infrastructure allows administration of eBEACOPP chemotherapy and assessment of metabolic response by [18F-flurodeoxyglucose]-PET,” wrote the investigators.

Related Videos
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.